PMC:7417114 / 46886-47620
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T241 | 154-160 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T242 | 361-365 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T243 | 590-594 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T66 | 361-365 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
| T67 | 590-594 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T461 | 304-307 | Disease | denotes | HSA | http://purl.obolibrary.org/obo/MONDO_0011848 |
| T462 | 348-373 | Disease | denotes | interstitial lung disease | http://purl.obolibrary.org/obo/MONDO_0015925 |
| T463 | 361-373 | Disease | denotes | lung disease | http://purl.obolibrary.org/obo/MONDO_0005275 |
| T464 | 410-428 | Disease | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/MONDO_0002771 |
| T465 | 577-602 | Disease | denotes | interstitial lung disease | http://purl.obolibrary.org/obo/MONDO_0015925 |
| T466 | 590-602 | Disease | denotes | lung disease | http://purl.obolibrary.org/obo/MONDO_0005275 |
| T467 | 688-706 | Disease | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/MONDO_0002771 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T549 | 154-160 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T550 | 304-307 | http://purl.obolibrary.org/obo/PR_000001932 | denotes | HSA |
| T551 | 361-365 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T552 | 361-365 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
| T553 | 395-396 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T554 | 590-594 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T555 | 590-594 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T408 | 11-17 | Chemical | denotes | Iressa | http://purl.obolibrary.org/obo/CHEBI_49668 |
| T409 | 204-206 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
| T410 | 299-302 | Chemical | denotes | AAG | http://purl.obolibrary.org/obo/CHEBI_73318 |
| T411 | 479-488 | Chemical | denotes | gefitinib | http://purl.obolibrary.org/obo/CHEBI_49668 |
| T412 | 559-568 | Chemical | denotes | gefitinib | http://purl.obolibrary.org/obo/CHEBI_49668 |
| T413 | 670-679 | Chemical | denotes | bleomycin | http://purl.obolibrary.org/obo/CHEBI_22907 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1491 | 253-259 | Gene | denotes | CYP3A4 | Gene:1576 |
| 1560 | 457-465 | Species | denotes | patients | Tax:9606 |
| 1593 | 0-9 | Chemical | denotes | Gefitinib | MESH:D000077156 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T125 | 348-373 | Phenotype | denotes | interstitial lung disease | http://purl.obolibrary.org/obo/HP_0006530 |
| T126 | 410-428 | Phenotype | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/HP_0002206 |
| T127 | 577-602 | Phenotype | denotes | interstitial lung disease | http://purl.obolibrary.org/obo/HP_0006530 |
| T128 | 688-706 | Phenotype | denotes | pulmonary fibrosis | http://purl.obolibrary.org/obo/HP_0002206 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T378 | 0-18 | Sentence | denotes | Gefitinib (Iressa) |
| T379 | 19-75 | Sentence | denotes | (AstraZeneca/Tiva) Bioavailability not affected by food; |
| T380 | 76-148 | Sentence | denotes | slowly absorbed following oral administration; mean bioavailability=60%. |
| T381 | 149-191 | Sentence | denotes | Peak plasma levels 3-7 h following dosing; |
| T382 | 192-285 | Sentence | denotes | Vd= 1400 L (IV administration) Metabolized mainly by hepatic CYP3A4 250 mg orally once daily; |
| T383 | 286-734 | Sentence | denotes | 90% binding (AAG, HSA) Associated with increased incidence of interstitial lung disease, which often acts as a precursor to pulmonary fibrosis; approximately 1 percent of patients treated with gefitinib develop pulmonary toxicity, within the first few months of treatment; gefitinib-related interstitial lung disease is generally uncommon (212) (213) (140) (214); shown to exacerbate bleomycin-induced pulmonary fibrosis in preclinical models (215) |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32778962-16735708-84130722 | 626-629 | 16735708 | denotes | 212 |
| 32778962-17052296-84130723 | 632-635 | 17052296 | denotes | 213 |
| 32778962-22076388-84130724 | 638-641 | 22076388 | denotes | 140 |
| 32778962-24332320-84130725 | 644-647 | 24332320 | denotes | 214 |
| 32778962-12941834-84130726 | 730-733 | 12941834 | denotes | 215 |